A Randomised, Single Dose Exposure Study to Assess the Safety, Tolerability and Pharmacokinetics of Investigational Captisol-Enabled® Budesonide Inhalation Solution (CBIS) Delivered via eFlow® Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® Jet Nebuliser in Children with Asthma

Trial Profile

A Randomised, Single Dose Exposure Study to Assess the Safety, Tolerability and Pharmacokinetics of Investigational Captisol-Enabled® Budesonide Inhalation Solution (CBIS) Delivered via eFlow® Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® Jet Nebuliser in Children with Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Budesonide (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Verus Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top